Radioimmunotherapy Market is Expected to Reach US$ 132.7 Mn by 2026

Treatment targeted to the actual malignant tissue without damaging the surrounding healthy tissues. The global radioimmunotherapy market was valued at US$ 81.9 Mn in 2018 and is expected to reach US$ 132.7 Mn by the year 2026, growing at a CAGR of 6.5% during the forecast period.

Conventional cancer treatments such as chemotherapy and radiation therapy have some inherent disadvantages, such as they are not targeted to the cancer cells, and they damage the surrounding healthy tissues. Due to this, chemotherapy and radiation therapy have various side effects, including but not limited to fatigue, gastrointestinal problems, pain, and skin changes. Radioimmunotherapy involves the use of a radiolabelled monoclonal antibody to kill cancer cells. Monoclonal antibodies are specific to the antigens that are expressed in very high quantities in tumor cells and hence, only tumor cells are targeted. Additionally, the radioisotopes used are either alpha or beta emitters which have a small tissue range. (Alpha particles - 50-100µm; beta particles - about 1.5mm). This further limit the damage to the surrounding healthy tissues.  Due to these advantages, the demand for radioimmunotherapy is expected to grow during the forecast period, thereby driving the market. However, Higher risk of immune mediated side-effects as compared to individual therapy and high therapy cost can restrain the growth of the market.

Get a Sample Copy @

Key Findings:

  • North America dominated the global market in 2018 and is expected to remain dominant over the forecast period
  • The beta emitting radioimmunotherapy market accounted for a share of 95.0% in 2018 and is anticipated to witness similar growth trends during the forecast year.
  • Leukemia is the next best segment for investment as leukemias are radiosensitive and therefore are more likely to respond to radioimmunotherapy.
  • Increasing number of hospitals and better facilities, along with the adequate number of experienced healthcare professionals are contribution to the growth of the radioimmunotherapy market in the hospital end-user segment.

 Recent News:

  • In 2019, Acrotech Biopharma acquired seven FDA approved products of Spectrum Pharmaceuticals, Inc., which include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, and KHAPZORY. This acquisition has strengthened the oncology and hematology product portfolio of the company. 
  • In 2019, Actinium Pharmaceuticals has come up with the phase 1 clinical trial’s result for Actimab-A in combination with CLAG-M and has accepted to present this result at the 2019 American Society of Hematology (ASH) annual meeting.
  • In 2019, Advanced Accelerator Applications have received the approval for Lutathera from the Israel Ministry of Health, for the treatment of Gastroenteropancreatic  Neuroendocrine Tumors.
  • In 2019, Bayer presented its cancer portfolio in American Society of Clinical Oncology Genitourinary. The presentation includes details regarding Xofigo, an approved drug for prostate cancer treatment.
  • In 2019, BioNTech acquired MabVax's preclinical antibody asset, in order to complement and expand its existing RiboMABS development capabilities and antibody portfolio.

In 2019, Nordic Nanovector ASA entered an agreement with Isotope Technologies Garching GmbH (ITG), a subsidiary of ITM Isotopen Technologien München AG. Owing to this agreement, the company procured Lutetium-177, a component of Betalutin

Quick Inquiry

Follow Us